UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Assessment of pancreatic β-cell function: review of methods and clinical applications

Current diabetes reviews, 2014-01, Vol.10 (1), p.2-42

2014

Volltextzugriff (PDF)

Understanding the kidneys' role in blood glucose regulation

The American journal of managed care, 2012-01, Vol.18 (1 Suppl), p.S11-S16

Triplitt, Curtis L

2012

Volltextzugriff (PDF)

124-OR: Effects of Dapagliflozin Therapy on Renal Hemodynamics in Type 2 Diabetes Patients

Diabetes (New York, N.Y.), 2023-06, Vol.72 (Supplement_1), p.1

2023

Volltextzugriff (PDF)

887-P: Renal Benefit of Dapagliflozin Therapy in Hyperfiltering Type 2 Diabetes Patients

Diabetes (New York, N.Y.), 2023-06, Vol.72 (Supplement_1), p.1

2023

Volltextzugriff (PDF)

Examining the mechanisms of glucose regulation

The American journal of managed care, 2012-01, Vol.18 (1 Suppl), p.S4-10

Triplitt, Curtis L

2012

Volltextzugriff (PDF)

Management of type 2 diabetes with oral semaglutide: Practical guidance for pharmacists

American journal of health-system pharmacy, 2021-03, Vol.78 (7), p.556-567

2021

Volltextzugriff (PDF)

A Special Thanks to Lyn Reynolds, Director of the ADA Editorial Office, as She Embarks on Her Retirement

Diabetes care, 2022-08, Vol.45 (8), p.1707-1708

2022

Volltextzugriff (PDF)

A Special Thanks to Lyn Reynolds, Director of the ADA Editorial Office, as She Embarks on Her Retirement

Diabetes (New York, N.Y.), 2022-08, Vol.71 (8), p.1601-1602

2022

Volltextzugriff (PDF)

857-P: Mechanisms of Dapagliflozin to Reduce Intraglomerular Pressure in Patients with Type 2 Diabetes

Diabetes (New York, N.Y.), 2022-06, Vol.71 (Supplement_1)

2022

Volltextzugriff (PDF)

99-LB: Myocardial Blood Flow in Association with Baseline Ejection Fraction after Elevation in Plasma Ketones in Patients with T2DM and Heart Failure

Diabetes (New York, N.Y.), 2023-06, Vol.72 (Supplement_1), p.1

2023

Volltextzugriff (PDF)

Oh, What Times We Live In

Diabetes spectrum, 2019-02, Vol.32 (1), p.3-4

Triplitt, Curtis L

2019

Volltextzugriff (PDF)

175-OR: Effect of Hyperketonemia on Cardiac Efficiency in Patients with Heart Failure and Type 2 Diabetes

Diabetes (New York, N.Y.), 2022-06, Vol.71 (Supplement_1)

2022

Volltextzugriff (PDF)

644-P: Effect of PharmacologIC (EPIC) Therapy on Insulin Sensitivity and Beta-Cell Function in Prediabetes (PreDM)

Diabetes (New York, N.Y.), 2022-06, Vol.71 (Supplement_1)

2022

Volltextzugriff (PDF)

68-LB: Early Pharmacological Intervention (EPIC) to Preserve Beta-Cell Function in Prediabetes (PreDM)

Diabetes (New York, N.Y.), 2023-06, Vol.72 (Supplement_1), p.1

2023

Volltextzugriff (PDF)

97-LB: Empagliflozin Improves Cardiopulmonary Function and VE/VCO2 in Patients with T2D and HFrEF

Diabetes (New York, N.Y.), 2023-06, Vol.72 (Supplement_1), p.1

2023

Volltextzugriff (PDF)

98-LB: Effects of SGLT2 Inhibition on Skeletal Muscle Bioenergetics and Myocellular Lipids in Patients with T2D and HFrEF

Diabetes (New York, N.Y.), 2023-06, Vol.72 (Supplement_1), p.1

2023

Volltextzugriff (PDF)

Improving Outcomes of People With Diabetes Through Overcoming Therapeutic Inertia

Diabetes spectrum, 2020-02, Vol.33 (1), p.5-6

2020

Volltextzugriff (PDF)

1070-P: Bromocriptine-QR (BQR) Ameliorates a Pro-oxidative Stress/Proinflammatory (POS/PI) Monocyte Phenotype in Poorly Controlled T2DM Subjects

Diabetes (New York, N.Y.), 2020-06, Vol.69 (Supplement_1)

2020

Volltextzugriff (PDF)

352-OR: Combination Therapy with Dapagliflozin plus Exenatide on Endogenous Glucose Production: A Mechanism of Action Study

Diabetes (New York, N.Y.), 2020-06, Vol.69 (Supplement_1)

2020

Volltextzugriff (PDF)

1136-P: Glucose Kinetics during Oral Glucose Challenge following Administration of Exenatide and Dapagliflozin Alone and in Combination in Type 2 Diabetes

Diabetes (New York, N.Y.), 2020-06, Vol.69 (Supplement_1)

2020

Volltextzugriff (PDF)

155-LB: The Increase in Endogenous Glucose Production with SGLT2 Inhibition Is Unchanged by Renal Denervation but Highly Correlates to Urinary Glucose Excretion

Diabetes (New York, N.Y.), 2019-06, Vol.68 (Supplement_1)

2019

Volltextzugriff (PDF)

246-OR: Contribution of Plasma Glucose and Hormones to the Acute Compensatory Rise in Endogenous Glucose Production (EGP) during Glucosuria in T2D Patients

Diabetes (New York, N.Y.), 2019-06, Vol.68 (Supplement_1)

2019

Volltextzugriff (PDF)

1166-P: Bromocriptine-QR (BQR) Therapy Reduces Elevated Sympathetic Nervous System Activity (SNSA) and Oxidative Stress (OS) in Type 2 Diabetes (T2D) Subjects whose Dysglycemia Is Poorly Controlled on GLP-1 Receptor Agonist (GLP-1RA)

Diabetes (New York, N.Y.), 2019-06, Vol.68 (Supplement_1)

2019

Volltextzugriff (PDF)

A Special Thanks to Lyn Reynolds, Director of the ADA Editorial Office, as She Embarks on Her Retirement

Diabetes spectrum, 2022-08, Vol.35 (3), p.320-321

2022

Volltextzugriff (PDF)

Novel Agents for the Treatment of Type 2 Diabetes

Diabetes spectrum, 2014-05, Vol.27 (2), p.100-112

2014

Volltextzugriff (PDF)

1 – 25 von 48

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(47)
Mit Volltextzugriff
(36)

Publikationsform

Artikel
(48)

Sprache

Englisch
(48)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

Diabetes
(29)
Diabetes Mellitus
(25)
Humans
(19)
Glucose
(14)
Metformin
(14)
Diabetes Mellitus, Type 2 - Drug Therapy
(13)
Blood Glucose
(12)
Hypoglycemic Agents - Therapeutic Use
(11)
Insulin
(11)
Comparative Studies
(10)
Research Design
(10)
Antidiabetics
(8)
Effectiveness
(8)
Effectiveness Studies
(8)
Female
(8)
Life Sciences & Biomedicine
(8)
Male
(8)
Metformin - Therapeutic Use
(8)
Reduction
(8)
Science & Technology
(8)

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

7 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Assessment of pancreatic β-cell function: review of methods and clinical applications

Understanding the kidneys' role in blood glucose regulation

124-OR: Effects of Dapagliflozin Therapy on Renal Hemodynamics in Type 2 Diabetes Patients

887-P: Renal Benefit of Dapagliflozin Therapy in Hyperfiltering Type 2 Diabetes Patients

Examining the mechanisms of glucose regulation

Management of type 2 diabetes with oral semaglutide: Practical guidance for pharmacists

A Special Thanks to Lyn Reynolds, Director of the ADA Editorial Office, as She Embarks on Her Retirement

A Special Thanks to Lyn Reynolds, Director of the ADA Editorial Office, as She Embarks on Her Retirement

857-P: Mechanisms of Dapagliflozin to Reduce Intraglomerular Pressure in Patients with Type 2 Diabetes

99-LB: Myocardial Blood Flow in Association with Baseline Ejection Fraction after Elevation in Plasma Ketones in Patients with T2DM and Heart Failure

Oh, What Times We Live In

175-OR: Effect of Hyperketonemia on Cardiac Efficiency in Patients with Heart Failure and Type 2 Diabetes

644-P: Effect of PharmacologIC (EPIC) Therapy on Insulin Sensitivity and Beta-Cell Function in Prediabetes (PreDM)

68-LB: Early Pharmacological Intervention (EPIC) to Preserve Beta-Cell Function in Prediabetes (PreDM)

97-LB: Empagliflozin Improves Cardiopulmonary Function and VE/VCO2 in Patients with T2D and HFrEF

98-LB: Effects of SGLT2 Inhibition on Skeletal Muscle Bioenergetics and Myocellular Lipids in Patients with T2D and HFrEF

Improving Outcomes of People With Diabetes Through Overcoming Therapeutic Inertia

1070-P: Bromocriptine-QR (BQR) Ameliorates a Pro-oxidative Stress/Proinflammatory (POS/PI) Monocyte Phenotype in Poorly Controlled T2DM Subjects

352-OR: Combination Therapy with Dapagliflozin plus Exenatide on Endogenous Glucose Production: A Mechanism of Action Study

1136-P: Glucose Kinetics during Oral Glucose Challenge following Administration of Exenatide and Dapagliflozin Alone and in Combination in Type 2 Diabetes

155-LB: The Increase in Endogenous Glucose Production with SGLT2 Inhibition Is Unchanged by Renal Denervation but Highly Correlates to Urinary Glucose Excretion

246-OR: Contribution of Plasma Glucose and Hormones to the Acute Compensatory Rise in Endogenous Glucose Production (EGP) during Glucosuria in T2D Patients

1166-P: Bromocriptine-QR (BQR) Therapy Reduces Elevated Sympathetic Nervous System Activity (SNSA) and Oxidative Stress (OS) in Type 2 Diabetes (T2D) Subjects whose Dysglycemia Is Poorly Controlled on GLP-1 Receptor Agonist (GLP-1RA)

A Special Thanks to Lyn Reynolds, Director of the ADA Editorial Office, as She Embarks on Her Retirement

Novel Agents for the Treatment of Type 2 Diabetes

Suchergebnisse filtern